Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Andreas Fibig to leave Bayer HealthCare Pharmaceuticals

Leverkusen, May 28, 2014 – Andreas Fibig (52), President of Bayer HealthCare Pharmaceuticals and a member of the Bayer HealthCare Executive Committee, will leave Bayer HealthCare to become Chief Executive Officer of International Flavors & Fragrances Inc., New York, NY, USA, effective September 1, 2014.

"With his experience and his commitment, Andreas Fibig has advanced the very positive development of our Pharmaceuticals business over the past years making it to one of the fastest growing pharmaceutical companies in the industry," said Olivier Brandicourt, CEO of Bayer HealthCare. "We thank him and wish him all the best for his next step in his career and his future."

The company will announce a successor for Andreas Fibig in a few days.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Jürgen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Constance Spitzer (+49-214-30-33021)
Dr. Olaf Weber (+49-214-30-33567)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.